Cargando…

Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases

BACKGROUND: Rosai–Dorfman disease (RDD) is a rare benign non-Langerhans cell histiocytic proliferative disease. RDD with central nervous system (CNS) involvement (CNS-RDD) is extremely rare. Its etiology is unclear, and there are no consensus recommendations for its treatment. More studies are neede...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xingshu, Yin, Wen, Guo, Youwei, He, Yi, Jiang, Zhipeng, Li, Yuzhe, Xie, Bo, Zhang, Seng, Jiang, Xingjun, Liu, Qing, Yuan, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669081/
https://www.ncbi.nlm.nih.gov/pubmed/36408161
http://dx.doi.org/10.3389/fonc.2022.1013419
_version_ 1784832054021586944
author Zhang, Xingshu
Yin, Wen
Guo, Youwei
He, Yi
Jiang, Zhipeng
Li, Yuzhe
Xie, Bo
Zhang, Seng
Jiang, Xingjun
Liu, Qing
Yuan, Jian
author_facet Zhang, Xingshu
Yin, Wen
Guo, Youwei
He, Yi
Jiang, Zhipeng
Li, Yuzhe
Xie, Bo
Zhang, Seng
Jiang, Xingjun
Liu, Qing
Yuan, Jian
author_sort Zhang, Xingshu
collection PubMed
description BACKGROUND: Rosai–Dorfman disease (RDD) is a rare benign non-Langerhans cell histiocytic proliferative disease. RDD with central nervous system (CNS) involvement (CNS-RDD) is extremely rare. Its etiology is unclear, and there are no consensus recommendations for its treatment. More studies are needed to elucidate the clinical and radiological manifestations and prognosis of CNS-RDD. METHODS: From January 2012 to June 2022, 12 patients with CNS-RDD (intracranial or spinal) were retrospectively evaluated, including collecting clinical data, imaging data, and pathological findings; summarizing imaging characteristics; and conducting follow-up studies on CND-RDD patient treatment and prognosis. RESULTS: Twelve CNS-RDD patients (nine male and three female patients, aged 12–67 years) were enrolled in this study. Nine patients represented convex and/or skull base RDD (eight with edema, six with lobulation and/or pseudopodium sign, four with multiple intracranial lesions), two patients had parenchymal RDD, and one patient had spinal cord subdural lesions. Symptoms of patients would vary according to the locations of the lesion, including but not limited to headaches, dizziness, seizures, cranial nerve dysfunction, and visual impairment. The immunohistochemistry of RDD showed positive expression of S100 and CD68 but not CD1a. Total resection (n = 7), subtotal resection (n = 3), partial resection (n = 1), and stereotaxic biopsy (n = 1) were achieved, respectively. A combination of chemotherapy plus steroid therapy was performed on two patients (relapsing case and residual lesion) and showed a remarkable effect. CONCLUSION: CNS-RDD, as a rare disease, presents a significant diagnostic challenge for clinicians. Solitary CNS-RDD are easily misdiagnosed as meningioma. However, when the MRI imaging of the disease represents dura-based masses with significant edema, homogeneous enhancement, lobulation, and/or pseudopodium sign, we should consider it might be the CNS-RDD. Surgery is an important and effective therapy for CNS-RDD. Steroids and chemotherapy are safe and effective for the postoperative treatment of relapsing cases or residual lesions.
format Online
Article
Text
id pubmed-9669081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96690812022-11-18 Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases Zhang, Xingshu Yin, Wen Guo, Youwei He, Yi Jiang, Zhipeng Li, Yuzhe Xie, Bo Zhang, Seng Jiang, Xingjun Liu, Qing Yuan, Jian Front Oncol Oncology BACKGROUND: Rosai–Dorfman disease (RDD) is a rare benign non-Langerhans cell histiocytic proliferative disease. RDD with central nervous system (CNS) involvement (CNS-RDD) is extremely rare. Its etiology is unclear, and there are no consensus recommendations for its treatment. More studies are needed to elucidate the clinical and radiological manifestations and prognosis of CNS-RDD. METHODS: From January 2012 to June 2022, 12 patients with CNS-RDD (intracranial or spinal) were retrospectively evaluated, including collecting clinical data, imaging data, and pathological findings; summarizing imaging characteristics; and conducting follow-up studies on CND-RDD patient treatment and prognosis. RESULTS: Twelve CNS-RDD patients (nine male and three female patients, aged 12–67 years) were enrolled in this study. Nine patients represented convex and/or skull base RDD (eight with edema, six with lobulation and/or pseudopodium sign, four with multiple intracranial lesions), two patients had parenchymal RDD, and one patient had spinal cord subdural lesions. Symptoms of patients would vary according to the locations of the lesion, including but not limited to headaches, dizziness, seizures, cranial nerve dysfunction, and visual impairment. The immunohistochemistry of RDD showed positive expression of S100 and CD68 but not CD1a. Total resection (n = 7), subtotal resection (n = 3), partial resection (n = 1), and stereotaxic biopsy (n = 1) were achieved, respectively. A combination of chemotherapy plus steroid therapy was performed on two patients (relapsing case and residual lesion) and showed a remarkable effect. CONCLUSION: CNS-RDD, as a rare disease, presents a significant diagnostic challenge for clinicians. Solitary CNS-RDD are easily misdiagnosed as meningioma. However, when the MRI imaging of the disease represents dura-based masses with significant edema, homogeneous enhancement, lobulation, and/or pseudopodium sign, we should consider it might be the CNS-RDD. Surgery is an important and effective therapy for CNS-RDD. Steroids and chemotherapy are safe and effective for the postoperative treatment of relapsing cases or residual lesions. Frontiers Media S.A. 2022-11-03 /pmc/articles/PMC9669081/ /pubmed/36408161 http://dx.doi.org/10.3389/fonc.2022.1013419 Text en Copyright © 2022 Zhang, Yin, Guo, He, Jiang, Li, Xie, Zhang, Jiang, Liu and Yuan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Xingshu
Yin, Wen
Guo, Youwei
He, Yi
Jiang, Zhipeng
Li, Yuzhe
Xie, Bo
Zhang, Seng
Jiang, Xingjun
Liu, Qing
Yuan, Jian
Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases
title Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases
title_full Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases
title_fullStr Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases
title_full_unstemmed Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases
title_short Rosai–Dorfman disease of the central nervous system: A clinical, radiological, and prognostic study of 12 cases
title_sort rosai–dorfman disease of the central nervous system: a clinical, radiological, and prognostic study of 12 cases
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669081/
https://www.ncbi.nlm.nih.gov/pubmed/36408161
http://dx.doi.org/10.3389/fonc.2022.1013419
work_keys_str_mv AT zhangxingshu rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT yinwen rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT guoyouwei rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT heyi rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT jiangzhipeng rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT liyuzhe rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT xiebo rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT zhangseng rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT jiangxingjun rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT liuqing rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases
AT yuanjian rosaidorfmandiseaseofthecentralnervoussystemaclinicalradiologicalandprognosticstudyof12cases